
Polymedco Appoints Chris Mathews as Chief Executive Officer and John McDonough as Executive Chairman to Advance Early Disease Detection
Polymedco, a leading provider of diagnostic testing solutions focused on early disease detection, has announced key leadership appointments as the company prepares for its next phase of growth. The company has promoted Chris Mathews to Chief Executive Officer (CEO) and appointed John McDonough as Executive Chairman of its Board of Directors. The appointments are intended to strengthen Polymedco’s leadership team as it continues to expand access to diagnostic technologies designed to support the early identification of colorectal cancer and heart attacks.
The leadership changes reflect the company’s continued focus on making screening and point-of-care diagnostic testing more accessible to healthcare providers and patients. Through its diagnostic solutions, Polymedco aims to help identify serious diseases at earlier stages, when timely medical intervention can have a meaningful impact on patient outcomes. Its work is centered on two important areas of healthcare: colorectal cancer screening and cardiac-marker testing.
With Mathews taking on the CEO role and McDonough serving as Executive Chairman, Polymedco brings together internal financial and operational leadership experience with extensive external expertise in the diagnostics industry. The appointments are expected to support the company’s strategic priorities, including expanding the availability of its technologies, strengthening its commercial capabilities and continuing to advance its mission of early disease detection.
Chris Mathews promoted to Chief Executive Officer
Chris Mathews has been promoted to Chief Executive Officer after serving as Polymedco’s Chief Financial Officer since 2022. During his time as CFO, Mathews has been involved in the company’s financial leadership and business operations, gaining experience with its strategy, organizational priorities and diagnostic testing portfolio.
His promotion represents a leadership transition that builds on his existing experience within the organization. Having served in a senior executive position at Polymedco, Mathews brings an understanding of the company’s business and its focus on expanding access to diagnostic technologies.
Before joining Polymedco, Mathews held leadership positions of increasing responsibility at Sanofi and Medtronic. His experience across these organizations provided exposure to the healthcare and medical technology industries, including the business and operational considerations involved in developing and delivering healthcare products and solutions.
Mathews holds a bachelor’s degree in finance and a Master of Business Administration (MBA) in international business and finance from the University of Georgia. His educational background combines financial expertise with an understanding of international business, supporting his experience in corporate leadership and strategic management.
As CEO, Mathews will lead Polymedco through its next stage of development, with a focus on building on the company’s established diagnostic technologies and expanding their reach. The company has emphasized that early detection remains central to its mission, particularly in conditions such as colorectal cancer and heart attacks, where identifying disease or relevant clinical indicators promptly can help support earlier medical evaluation and treatment.
“I’m honored to lead Polymedco in its next phase of growth and to build on decades of evidence showing the benefits of using our technology,” Mathews said. “The data are powerful—early detection saves lives. My leadership team and I are committed to expanding access to these cost-effective screening and point-of-care testing solutions.”
His comments highlight the company’s intention to build on the evidence supporting its diagnostic technologies while pursuing broader access to screening and testing solutions. The emphasis on cost-effective approaches also reflects the importance of developing diagnostic options that can be incorporated into healthcare settings and used to support timely clinical decisions.
John McDonough appointed Executive Chairman
Alongside Mathews’ promotion, Polymedco has appointed John McDonough as Executive Chairman of the Board of Directors. McDonough brings extensive leadership experience in the diagnostics sector, particularly in the development and commercialization of advanced diagnostic solutions.
Throughout his career, McDonough has held senior executive and chief executive positions across numerous private and publicly traded diagnostics companies. His experience includes leadership responsibilities involving business strategy, product commercialization and organizational development within the diagnostic technology market.
McDonough currently serves as Chairman and Board member of Cytrellis Biosystems and as a Board member at Highland Instruments. These roles provide him with continued involvement in healthcare technology and diagnostics-related businesses.
Previously, he served as Chairman, President and Chief Executive Officer of Sunbird Biosystems and T2 Biosystems. His leadership experience at these companies adds to his background in managing diagnostic organizations and advancing technologies through commercial development.
His appointment gives Polymedco access to an executive with experience across multiple stages of diagnostics business development. The diagnostics industry requires companies to address several challenges, including technology development, clinical validation, commercialization, healthcare provider adoption and market access. McDonough’s experience across private and public companies is relevant to these areas as Polymedco continues to pursue its growth objectives.
As Executive Chairman, McDonough will contribute his industry knowledge and leadership experience to the company’s strategic direction. His appointment also brings a personal connection to Polymedco’s mission, particularly its focus on colorectal cancer screening and early detection.
“Polymedco’s mission resonates deeply with me, both professionally and personally,” McDonough said. “Having experienced the impact colorectal cancer can have on families, I understand the importance of expanding access to effective screening and early detection tools that can save lives.”
McDonough’s statement underscores the significance of early detection beyond the commercial and technological aspects of diagnostics. Colorectal cancer can have a substantial impact on patients and their families, and screening plays an important role in identifying potential disease at an earlier stage. His personal experience reinforces his commitment to the company’s efforts to make effective screening technologies more widely accessible.
Strengthening leadership to support the company’s growth strategy
The appointments of Mathews and McDonough represent an important leadership development for Polymedco as it continues to advance its diagnostic testing business. The combination of Mathews’ experience as the company’s CFO and his previous leadership roles at Sanofi and Medtronic, together with McDonough’s extensive background in diagnostics, provides complementary expertise at the executive and board levels.
Mathews’ familiarity with Polymedco’s financial operations and business priorities offers continuity as he assumes responsibility for the company’s overall leadership. His experience in the pharmaceutical and medical technology sectors also provides a foundation for overseeing the company’s strategic and commercial objectives.
McDonough’s background, meanwhile, brings additional experience in the diagnostics industry, including leadership at companies focused on developing and commercializing diagnostic technologies. His involvement with other healthcare and technology organizations also reflects his continued engagement with the sector.
Together, the two leaders are positioned to support Polymedco as it works to expand access to its screening and point-of-care testing solutions. The company has identified early disease detection as a central priority, with particular attention to colorectal cancer and cardiac-marker screening.
The leadership changes come at a time when early diagnosis remains an important objective across healthcare systems. Diagnostic testing can help clinicians identify signs of disease, assess patient risk and determine whether additional evaluation or treatment is needed. In conditions such as colorectal cancer and cardiovascular emergencies, timely identification can be especially important.
Polymedco’s focus on screening and point-of-care testing reflects the role of accessible diagnostic technologies in supporting healthcare delivery. Screening solutions can help identify individuals who may require further assessment, while point-of-care tests can provide information in clinical settings to support more timely decision-making.
Advancing colorectal cancer screening and cardiac-marker testing
Polymedco’s mission is built around the principle that identifying disease early can improve opportunities for effective intervention. The company focuses on diagnostic testing solutions intended to support the detection of colorectal cancer and heart attacks.
Colorectal cancer screening is an important part of preventive healthcare because it can help identify individuals who need additional diagnostic evaluation. Screening programs are designed to detect potential signs of disease before symptoms become apparent or while treatment options may be more effective. Improving access to screening technologies is therefore an important consideration for healthcare providers, diagnostic companies and public health initiatives.
Cardiac-marker testing represents another important area of Polymedco’s work. Cardiac biomarkers can help healthcare professionals evaluate potential heart-related conditions, including situations in which a heart attack is suspected. Timely testing and clinical assessment can contribute to decisions about further investigation and patient management.
By focusing on these areas, Polymedco aims to support healthcare professionals with diagnostic solutions that can be integrated into screening and point-of-care testing pathways. The company has highlighted the importance of cost-effective testing options and broader access as it works to advance its mission.
Mathews’ promotion to CEO signals the company’s intention to build on its existing technology portfolio and expand the reach of its diagnostic solutions. His stated commitment to increasing access to screening and point-of-care testing reflects the company’s focus on making early detection tools available to more healthcare providers and patients.
McDonough’s appointment further supports this direction by adding experienced diagnostics leadership at the board level. His history of leading diagnostics companies through development and commercialization provides relevant industry experience as Polymedco continues to pursue its objectives.
Leadership aligned with Polymedco’s mission
The new leadership structure brings together executives with complementary professional backgrounds and a shared focus on diagnostic innovation and early disease detection. Mathews will lead the company as CEO, drawing on his experience within Polymedco and his previous roles at Sanofi and Medtronic. McDonough will serve as Executive Chairman, contributing decades of experience in diagnostics leadership and commercialization.
Both appointments reinforce the company’s commitment to expanding access to diagnostic technologies that support earlier identification of serious health conditions. Their combined leadership experience is expected to help guide Polymedco’s business priorities as it continues developing its position in the diagnostic testing market.
The company has emphasized that its mission extends beyond providing testing solutions. Its broader objective is to help healthcare professionals identify disease earlier, enabling patients to receive appropriate evaluation and care when it may have the greatest impact.
For colorectal cancer, this means supporting wider access to screening technologies that can help identify individuals who may need further assessment. In cardiac care, it means advancing access to testing solutions that help clinicians evaluate cardiac markers and respond to potential heart-related emergencies.
As Polymedco enters this next phase under Mathews’ leadership and with McDonough as Executive Chairman, the company intends to build on its established diagnostic technologies and the evidence supporting their use. The appointments mark a significant step in strengthening the organization’s leadership as it works to expand its reach and advance early detection across cancer screening and cardiac-marker testing.
Healthcare professionals, partners and other interested stakeholders can learn more about Polymedco’s diagnostic technologies and its solutions for cancer and cardiac-marker screening by visiting the company’s official website at www.polymedco.com.
About Polymedco
Polymedco is a leader in diagnostic solutions focused on the early detection of disease. For more than four decades, the company has partnered with laboratories, health systems, and healthcare providers to improve patient outcomes through innovative screening and diagnostic technologies. Its portfolio includes OC-Auto® FIT, a leading fecal immunochemical test for colorectal cancer screening, and PATHFAST®, a near-patient testing platform delivering rapid, lab-quality cardiac results at the point of care.



